A Phase 4 interventional study of Mesalazine and Mesalazine in Ulcerative Colitis, sponsored by Flemming Bendtsen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-09-26.
Sponsored by Flemming Bendtsen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing mesalamine in Colitis, Ulcerative — 5 open to participants now, 6 under way, 1 of them phase 3. Mesalamine · Colitis, Ulcerative.
Among the 50 studies testing mesalamine in Colitis, Ulcerative, this one is the 26th largest by planned enrollment of the 49 interventional ones that give a count, is the only one that started in 2019, is one of 13 in phase 4, and was the 43rd registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 50 studies testing mesalamine in Colitis, Ulcerative are open now, in 3 countries. Recruiting first, the newest first:
The Second Hospital of Nanjing Medical University · Sites in China
Ages 18–75
University Hospital, Linkoeping · Sites in Sweden
Ages 18–70
Post Graduate Institute of Medical Education and Research, Chandigarh
Ages 18+
Faes Farma, S.A.
Ages 18+
By country, each count listing its studies:
Mesalamine: first FDA approval 1987 (ROWASA). What it is approved for, and how studies give it, is on its page →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 2 · Phase 3 26 · Phase 4 13
First in 2000; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 206 across the 49 interventional studies. Of the 42 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 50 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Flemming Bendtsen as lead sponsor.
Flemming Bendtsen has 1 study filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing mesalamine in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Several oral mesalazine (5-ASA) formulations exist, but the regimes require several tablets per day. Such regimens are not ideal and can interfere with normal daily activities of patients. Non-adherence has been associated with an increase in the risk of relapse and worse disease course; leading to a decrease in quality of life, an increase in societal and personal costs, and worst case increases the risk of colorectal cancer. Recently, a new formula for 5-ASA has been approved by the Danish Medicine Agency, with a single tablet regime per day.
Primary purpose:
Secondary purposes:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have had a relapse within the last 2 years
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1600 mg mesalazine (Asacol) treatment regimen (1 tablet per day) for a year
Drug: Mesalazine
800 mg mesalazine (Asacol) treatment regimen (3 tablets per day) for a year
Drug: Mesalazine
1600 mg Asacol \[mesalazine\]
800 mg Asacol \[mesalazine\]
Medical Adherence
Measured by drug accountability log Patients having taken ≥80 % are categorised as adherent
Time frame: through study completion, an average of 2 year
Medical Adherence
Measured by "Medical adherence rating scale" (MARS) Medical adherence rating scale is a self-reported medical adherence tool consisting of 5 items scored on a 5 point Likert scale (ranging from 5-25). The scale has been used in several IBD studies and a global score \> 20 indicates a good adherence.
Time frame: through study completion, an average of 2 year
Medical Adherence
Measured byf drug accountability log (outcome 1) and "Medical adherence rating scale" (MARS, outcome 2) separately, excl. pregnant and breastfeeding women. Further detail see outcome 1 and 2
Time frame: through study completion, an average of 2 year
Assessment of disease activity by Mayo Score
The Mayo Score is composed of 4 items. A score from 0-2 is categorised as remission and 11-12 as severe.
Time frame: through study completion, an average of 2 year
Assessment of disease activity by the Simple clinical colitis activity index (SCCAI)
The SCCAI rely solely on clinical assessments. Clinical remission are defined as SCCAI \< 1 and clinical response as a change of at least 1 point.
Time frame: through study completion, an average of 2 year
Assessment of endoscopic severity by the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
The UCEIS endoscopic severity on a scale of 1-4. Higher score mean worse disease severity.
Time frame: through study completion, an average of 2 year
Assessment of endoscopic severity by the Mayo endoscopic score
The Mayo endoscopic score is scored on a scale of 0-3. Higher score mean worse disease severity.
Time frame: through study completion, an average of 2 year
Assessment of histological severity by the Geboes score
The Geboes score is interpreted as such: a higher score means higher disease activity.
Time frame: through study completion, an average of 2 year
Assessment of histological severity by the Nancy Index
The Nancy Index are interpreted as such: The grade 4 correspond to severe disease, grade 0 as " absence of significant histological disease".
Time frame: through study completion, an average of 2 year
Assessment of histological severity by the Robarts Histopathology Index (RHI)
The RHI are interpreted as such: The score are ranging between 0 (no disease activity) to 33 (severe disease activity).
Time frame: through study completion, an average of 2 year
Correlation between the different clinical scores
Comparison, correlation and association between the different endoscopic, histological and disease activity indices. Included will be: Mayo score, Simple clinical colitis activity index (SCCAI), Ulcerative Colitis Endoscopic Index of Severity (UCEIS), Nancy Index, Robarts Histopathology Index (RHI) and the Geboes score (see outcome 4-10).
Time frame: through study completion, an average of 2 year
Remission - days
Differences in number of days in remission during the trial
Time frame: through study completion, an average of 2 year
Relapse - days
Differences in number of days in relapse during the trial
Time frame: through study completion, an average of 2 year
Remission and relapse - episodes
Differences episodes of relapses during the trial
Time frame: through study completion, an average of 2 year
Changes in quality of life
Prospective analyses of quality of life using 12-Item Short Form Survey (SF12). The SF12 is measured on a global score from 12-56. Beside a global score, a mental and physical dimension will also be calculated.
Time frame: through study completion, an average of 2 year
Changes in disease specific quality of life
Prospective analyses quality of life using the Short inflammatory bowel disease questionnaire (SIBDQ) The SIBDQ is a quality of life (QOL) questionnaire ranging from 10-70. Higher score means better QOL.
Time frame: through study completion, an average of 2 year
Changes in disability among ulcerative colitis patients
Prospective analyses of disability using the Inflammatory bowel disease disability index (IBD-DI) The IBD-DI measures the disability among patients with inflammatory bowel disease. Higher scores means worse disability.
Time frame: through study completion, an average of 2 year
Changes in sleep quality
Prospective analyses of sleep using the Pittsburgh Sleep Quality Index (PSQI), The PSQI was designed to measure sleep quality and disturbance. A global score \> 5 is considered poor sleep quality.
Time frame: through study completion, an average of 2 year
Changes in resilience
Prospective analyses of resilience using the Brief Resilience Scale (BRS) The BRS is designed to measure the ability to bounce back or recover from stressful events. Higher scores means higher resilience.
Time frame: through study completion, an average of 2 year
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
No publications or documents are linked to this record.
Started Nov 2019 (actual). Primary completion is estimated for Dec 2024, 61 months after the start.
Of 48 non-industry phase 4 interventional studies under Colitis, Ulcerative, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 66. This study's planned 61 months is close to that.
Counting every sponsor, half of 63 studies reached it within 43 months; a quarter within 25 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mesalamine